1
|
Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, Fumet JD, Latour C, Rébé C, Bellaye PS, Kaderbhaï CG, Spill A, Collin B, Callanan MB, Lagrange A, Favier L, Coudert B, Arnould L, Ladoire S, Routy B, Joubert P, Ghiringhelli F. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell 2022; 40:136-152.e12. [PMID: 35051357 DOI: 10.1016/j.ccell.2021.12.009] [Citation(s) in RCA: 70] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 10/21/2021] [Accepted: 12/10/2021] [Indexed: 12/17/2022]
Abstract
Chemotherapy with anti PD-1/PD-L1 antibodies has become the standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). Using lung tumor models, where pemetrexed and cisplatin (PEM/CDDP) chemotherapy remains unable to synergize with immune checkpoint inhibitors (ICIs), we linked the failure of this treatment with its inability to induce CXCL10 expression and CD8+ T cell recruitment. Using drug screening, we showed that combining a MEK inhibitor (MEKi) with PEM/CDDP triggers CXCL10 secretion by cancer cells and CD8+ T cell recruitment, sensitizing it to ICIs. PEM/CDDP plus a MEKi promotes optineurin (OPTN)-dependent mitophagy, resulting in CXCL10 production in a mitochondrial DNA- and TLR9-dependent manner. TLR9 or autophagy/mitophagy inhibition abolishes the anti-tumor efficacy of PEM/CDDP plus MEKi/anti-PD-L1 therapy. In human NSCLCs, high OPTN, TLR9, and CXCL10 expression is associated with a better response to ICIs. Our results underline the role of TLR9- and OPTN-dependent mitophagy in enhancing chemoimmunotherapy efficacy.
Collapse
Affiliation(s)
- Emeric Limagne
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France.
| | - Lisa Nuttin
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Marion Thibaudin
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Elise Jacquin
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; INSERM UMR-S 1193, Université Paris-Saclay, Châtenay-Malabry, France
| | - Romain Aucagne
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France; CRISPR Innovative Genomics (CRIGEN) Platform, Unit for Innovation in Genetics and Epigenetics in Oncology (IGEO), Dijon University Hospital, 21000 Dijon, France
| | - Marjorie Bon
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Solène Revy
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Robby Barnestein
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Elise Ballot
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Caroline Truntzer
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Valentin Derangère
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Jean-David Fumet
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Department of Medical Oncology, Centre Georges-François Leclerc, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Charlène Latour
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Cédric Rébé
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Pierre-Simon Bellaye
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Nuclear Medicine Unit, Preclinical Imagery and Radiotherapy Platform, Centre Georges-François Leclerc, 21000 Dijon, France
| | | | - Aodrenn Spill
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Bertrand Collin
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Nuclear Medicine Unit, Preclinical Imagery and Radiotherapy Platform, Centre Georges-François Leclerc, 21000 Dijon, France; Institut de Chimie Moléculaire de l'Université; de Bourgogne, UMR CNRS 6302, 21000, Dijon, France
| | - Mary B Callanan
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France; CRISPR Innovative Genomics (CRIGEN) Platform, Unit for Innovation in Genetics and Epigenetics in Oncology (IGEO), Dijon University Hospital, 21000 Dijon, France
| | - Aurélie Lagrange
- Department of Medical Oncology, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Laure Favier
- Department of Medical Oncology, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Bruno Coudert
- Department of Medical Oncology, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Laurent Arnould
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Unit of Pathology, Department of Biology and Pathology of the Tumors, Centre Georges-François Leclerc, 21000 Dijon, France
| | - Sylvain Ladoire
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Department of Medical Oncology, Centre Georges-François Leclerc, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France
| | - Bertrand Routy
- University of Montreal Research Center (CRCHUM), Montreal, QC, Canada
| | - Philippe Joubert
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, QC, Canada
| | - François Ghiringhelli
- University of Bourgogne Franche-Comté, 21000 Dijon, France; Department of Medical Oncology, Centre Georges-François Leclerc, 21000 Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Equipe Labellisée Ligue Contre le Cancer, 21000 Dijon, France; Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France; Genetic and Immunology Medical Institute, Dijon, France.
| |
Collapse
|